Benzinga | Sep 30, 2021 04:31PM EDT

Monte Rosa Therapeutics To Present Late-breaking Preclinical Data On Targeting GSPT1 For Myc-driven Cancers At AACR-NCI-EORTC Virtual International Conference

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that preclinical data for the company's GSPT1-directed molecular glue degrader targeting Myc-driven breast cancer has been selected for a late-breaking poster presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics from Oct. 7-10.